Latest:
Opinion: The Legal and Regulatory Year in Review
Intellectual property law attorneys from Axinn discuss regulatory and legal events in 2020 that will affect biosimilar markets in 2021.
© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.
Authors
Christina Corridon, MPH, MBA
Christina Corridon, MPH, MBA, is a principal in
Latest:
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Rabiah Dys, PharmD
Rabiah Dys, PharmD, is Senior Vice President of Clinical Program Development and Fellowship Program Director on Health Equity and Systems Thinking for CPS Solutions
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Ashley Gallagher
Ashley Gallagher is an associate editor for Pharmacy Times.
Latest:
Dr Lakesha Farmer Highlights Current Biosimilar Education, Acceptance Efforts
Cencora's Lakesha Farmer, PharmD, MBA, discusses efforts that health care organizations can take to better educate patients and providers on biosimilars to improve biosimilar acceptance and achieve cost savings associated with these products.
Advertisement
Advertisement